Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914
This study is recruiting at 18 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer
- Colorectal Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Endometrial Cancer
- Solid Tumor, Adult
- KRAS G12D
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Research Site · Duarte, CA
- Research Site · Los Angeles, CA
- Research Site · Newport Beach, CA
Florida · 1
- Research Site · Jacksonville, FL
Illinois · 1
- Research Site · Chicago, IL
Kansas · 1
- Research Site · Westwood, KS
Massachusetts · 1
- Research Site · Boston, MA
Missouri · 1
- Research Site · St Louis, MO
New York · 2
- Research Site · New York, NY
- Research Site · New York, NY
Oregon · 1
- Research Site · Portland, OR
Pennsylvania · 2
- Research Site · Philadelphia, PA
- Research Site · Pittsburgh, PA
Tennessee · 1
- Research Site · Nashville, TN
Texas · 3
- Research Site · Dallas, TX
- Research Site · Galveston, TX
- Research Site · Houston, TX
Wisconsin · 1
- Research Site · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.